Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals and keeping the price target at $43.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Debanjana Chatterjee’s rating is based on the promising outlook for EyePoint Pharmaceuticals, particularly with its wet AMD therapy, Duravyu, which is expected to have pivotal trial readouts by 2026. The company has pursued a well-established regulatory path for wet AMD approval, which is seen as a strategic advantage compared to other companies taking more innovative approaches.
EyePoint’s financial position is also strong, with significant cash reserves that provide a solid foundation for its ongoing and future research and development activities. The market dynamics and potential paradigm shifts in wet AMD treatments further support the Buy rating, as EyePoint’s therapies could play a significant role in addressing unmet needs in this space.
In another report released on December 9, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EYPT in relation to earlier this year.